Biogen is opening its wallet in a big way, agreeing to buy Apellis Pharmaceuticals in an all-cash deal that values the Waltham biotech at about $5.6 billion. The offer of $41 a share hands Biogen control of Apellis’ pegcetacoplan programs, including marketed products and late-stage work in rare kidney diseases. It is a clear swing at pushing beyond Biogen’s core neurology roots into nephrology and rare-disease medicine, as reported by Bloomberg.
Under the agreement, Biogen will pay $41 per share for Apellis, valuing the deal at roughly $5.6 billion, according to Bloomberg. The outlet notes that the price represents a premium to recent trading levels and comes as Apellis has been moving systemic pegcetacoplan into kidney indications.
Apellis developed pegcetacoplan, sold as SYFOVRE for geographic atrophy via intravitreal injection and as EMPAVELI/Aspaveli for paroxysmal nocturnal hemoglobinuria. The company has also been pursuing the drug in rare kidney disorders such as C3 glomerulopathy and primary IC-MPGN, according to Apellis investor materials. Those kidney-disease programs, along with recent regulatory filings, are among the central assets Biogen would pick up in the transaction.
Strategic Rationale
Bloomberg reports that Biogen is aiming to beef up its kidney franchise while broadening its immunology and rare-disease lineup as growth in some neurology businesses slows. The deal would rank among Biogen’s larger acquisitions, signaling that the company is prepared to lean on mergers and acquisitions to diversify its pipeline rather than relying only on homegrown R&D.
Market Reaction
Heading into the announcement, Apellis shares had been trading well below the offer price and were down roughly 30 percent year to date, according to CNBC. Investors will be watching whether Biogen ultimately uses only cash for the purchase and how it plans to integrate Apellis’ commercial and research teams into its broader organization.
What Comes Next
The deal is still subject to the usual closing conditions and regulatory approvals, and neither company has put a public deadline on when they expect it to wrap up. Apellis’ recent SEC filings point out that transactions of this size typically need shareholder approvals and can face antitrust and other regulatory reviews that might influence timing and terms, complete with the standard caveats and forward-looking language.
Local Biotech Angle
Both companies sit squarely in the Greater Boston life-sciences cluster. Apellis is based in Waltham and Biogen runs a major hub in Cambridge, so the deal will be watched closely by local investors, service providers and academic collaborators. Depending on how Biogen handles integration, the acquisition could reshape hiring, lab footprints and partnership dynamics across the Boston-area biotech scene.
For now, the proposed tie-up is a fast-moving story that links a marketed complement inhibitor, an expanding rare-disease push and a broader industry trend of shoring up pipelines through targeted acquisitions.
